No Data
No Data
Damo: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $10.00 to $4.00.
Damo: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $10.00 to $4.00.
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $4
Morgan Stanley analyst Tejas Savant maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $10 to $4.
Ambry Genetics And PacBio Selected By UCI And GREGoR Consortium To Support Pediatric Mendelian Genomics Research Center Program To Study Rare Diseases
Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing sol
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center ProgramALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ --Ambry Genetics, a p
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining around 20 points on Tuesday.Shares of Sony Group Corporation (NYSE:SONY) rose sharply during Tuesday's session after the company reported better-tha
No Data